Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...

CURE: Can you explain what this FDA approval of Enhertu means for patients with HER2-low or HER2-ultralow metastatic breast cancer? How does it change treatment options? Tripathy: We've [seen] from ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

"There is currently a lack of clinical trial data directly comparing trastuzumab ... AZ licensed rights to Enhertu in 2019 for a hefty $1.35 billion upfront in a deal that could be worth up ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Nadia Sawalha via X.com Sawalha is one of the 'Fab Four' women, alongside friends Hannah Gardner – who has stage 4 breast cancer and received Enhertu through a clinical trial – Helen Addis ...